AB1233 GENDER DIFFERENCE IN DISEASE SEVERITY AND TREATMENT OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA), AXIAL SPONDYLOARTHRITIS (AXSPA) AND PSORIATIC ARTHRITIS (PSA) STARTING TREATMENT WITH TARGETED THERAPY IN THE CZECH REPUBLIC. (2nd June 2020)

• Record Type: Journal Article
• Authors: Zavada, J.; Nekvindova, L.; Pavelka, K.; Horak, P.; Vencovský, J.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 1907
• Page End: 1908
• Publication Date: 2020-06-02
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.2849
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The ATTRA registry captures more than 95% of patients with RA, AxSpA, or PSA treated with biologics in the Czech Republic (CZ). In CZ, anti-TNF therapy is reimbursed for RA if DAS28>5.1 despite therapy with csDMARDs, for PSA if disease is not "adequately controlled" with csDMARDs and for AS if BASDAI>4 and CRP/ESR elevated above normal. Objectives: We aimed to investigate gender-related differences in baseline characteristics and treatment effectiveness among patients with RA, AxSpa, and PsA starting first targeted therapy (TT) in CZ. Methods: In this observational cohort study, the ATTRA register provided prospectively collected data on RA, AxSpA and PsA patients who initiated their first TT (mostly by TNFi) in 2012–6/2018. Treatment effectiveness and adherence was assessed at 12 months by a change in patient-reported outcomes (PROs), CRP and % drug survival. Differences in categorical and continuous data btw males and females were assessed using the Pearson X 2 test (of Fisher exact test, as appropriate), or Mann-Whitney test resp. This study was largely descriptive, and no statistical adjustments have been made. Results: A total of 1602 RA, 1306 AxSpa, and 493 PsA patients were included. The difference in baseline characteristics btw women and men starting TT are shown in table 1. Their response and adherence to TT after one year is shown in table 2. Conclusion: When starting their first TT, males tended to have higher levels of CRP, while females were more often (ex)smokers and reported worse parameters of quality of life across the diagnostic groups. The improvement of PROs was similar in males and females, while males with axSpA and PsA showed larger improvements in CRP. Survival on drug at one year was similar, save for AxSpA, where males showed better survival. References: Acknowledgments: Supported by project 00023728 of Ministry of Health, CZ Disclosure of Interests: Jakub Zavada Speakers bureau: Abbvie, UCB, Sanofi, Elli-Lilly, Novartis, Zentiva, Accord, Lucie Nekvindova: None declared, Karel Pavelka Consultant of: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Speakers bureau: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Pavel Horak Speakers bureau: Pfizer, Abbvie, Eli lilly. Novartis, Roche, Sanofi, Jiří Vencovský: None declared